IMMUNOCORE
Recently, Immunocore announced its full-year 2023 results, with net revenue of $67.6 million in the fourth quarter of 2023, and full-year 2023 net revenue of $249 million, or $1.79 billion yuan ($7.1994 yuan), up 43% year on year. Cash and cash equivalents as at December 31,2023 were $442 million; the convertible senior notes issued in February 2024 will result in a net gain of $389.3 million.
KIMMTRAK Full-year 2023 net sales reached $238.7 million, with net sales of $67.6 million in the fourth quarter. Among the 35 countries approved by the KIMMTRAK, net sales in the United States reached $169.8 million, $67.6 million in Europe, and $1.3 million internationally. The increase was mainly due to increased sales in the United States and expansion in global countries.
About the KIMMTRAK
As the world's first regulatory approved T cell receptor (TCR) therapy, kimmtrak is a fusion protein of TCR targeting gp 100 and scFv targeting CD3, approved for the treatment of uveal melanoma patients with the HLA-A * 02:01 genotype (ophthalmology). KIMMTRAK Beat K and CTLA-4 mAb in phase III clinical data and was approved by the FDA on January 26,2022. The US pricing KIMMTRAK is set at $400,000 a year.
Kimmtrak Cell therapy is developed based on Immunocore's ImmTAC technology platform. The platform is a technology platform for constructing the fusion of the CD3 antibody domain with the TCR molecules. The T cell receptor (TCR) targeting cancer cells can be optimized and coupled to the immune effector domain against CD3 to recognize and kill specific cancer cells. However, unlike Car-T, TCR-T cell therapy still relies on specific MHC molecules to present the antigen, so its efficacy is related to the HLA typing of patients.
About the Immunocore
Immunocore Is a pioneering T cell receptor biotechnology company in the commercialization stage dedicated to develop and commercializing a new generation of transformative drugs to meet the unmet needs in the fields of cancer, infectious diseases and autoimmune diseases.
Immunocore The initial treatment focus is oncology, the leading program for metastatic uveal melanoma (a rare eye cancer) potential therapy —— tumor TCR therapy KIMMTRAK has been approved.
Using its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing deep pipelines across multiple therapeutic areas, including five clinical stage programs in oncology and infectious diseases, advanced preclinical programs for autoimmune diseases, and multiple early preclinical programs.
Immunocore Development pipeline
sum up
The progress of TCR therapy is very slow, but the therapeutic potential of TCR therapy in the field of solid tumors can not be underestimated, and many domestic and foreign pharmaceutical companies are optimistic about this field. Immunocore Has been leading in the TCR therapy, Adaptimmune followed, such as novartis, constant and other big drug companies at home and abroad, China has become the global TCR-T clinical application number second, sweet snow precision, star hand biological, day, biology, excellent, immune, Shenzhen, Guangzhou grace biological medicine, Beijing can biological on the layout of TCR therapy.
Xiangxue Pharmaceutical TCR-T therapy targeting NY-ESO-1: TAEST16001 has been approved by the State Food and Drug Administration to enter the new drug clinical trial, and is the first TCR-T cell drug to enter the registration system clinical trial in China.
Starhand Bio's SCG101 became the world's first IND approved TCR-T cell therapy for cholangiocarcinoma.
Reference: immunocore official website
